[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645032":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":40,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Kanuni Sultan Suleyman Training and Research Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Postmenopausal Women Undergoing Osteoporosis Evaluation",null,"Postmenopausal women undergoing routine osteoporosis assessment will be included in this observational cohort. Participants will undergo bone mineral density measurement, routine osteoporosis laboratory evaluation, FRAX assessment, handgrip strength measurement, and serum lumican analysis. No treatment or interventional procedure will be administered as part of the study.",[13],{"name":14,"affiliation":15,"role":16},"Dilek Ün oguzhanasiltürk, MD","Kanuni Sultan and Süleyman Training Resarch Hospital","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Dilek Ün Oğuzhanasiltürk, MD","CONTACT","+90 5056367184","dilekunoguzhan@gmail.com",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":10,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey","RECRUITING","Küçükçekmece","Istanbul","34303","Turkey (Türkiye)",{"type":32,"coordinates":33},"Point",[34,35],28.77123,40.99104,{"lat":35,"lon":34},[38],{"name":19,"role":20,"phone":39,"phoneExt":10,"email":22},"+905056367184",{"type":16,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Dilek ün oguzhanasilturk","Physical Medicine and Rehabilitation Specialist","100645032","can-serum-lumican-level-identify-a-hidden-fragility-phenotype-beyond-bone-mineral-density-in-postmenopausal-women-100645032",false,"NCT07677072","Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?","LUMINOS","Inclusion Criteria:\n\nInclusion Criteria:\n\n* Female sex\n* Age 45 years or older\n* Postmenopausal status\n* Attendance at the Physical Medicine and Rehabilitation outpatient clinic\n* Undergoing routine bone mineral density (DEXA) assessment and osteoporosis laboratory evaluation\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\nExclusion Criteria:\n\n* Premenopausal women\n* Secondary causes of osteoporosis (e.g., malignancy, advanced renal failure, severe liver disease, significant endocrine disorders)\n* Active infection or acute inflammatory disease\n* Major surgery within the previous 6 months\n* Neurological or muscular disorders that may significantly affect muscle function\n* Inability to comply with study procedures and assessments\n* Current treatment with medications that significantly affect bone metabolism, including bisphosphonates, denosumab, teriparatide, or other anti-osteoporotic agents\n* Refusal or inability to provide written informed consent","FEMALE","45 Years",{"count":53,"type":54},98,"ESTIMATED","OBSERVATIONAL","Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.",[58,59,60,61],"Osteoporosis","Postmenopausal Osteoporosis","Frailty","Fragility Fractures",[63,58,64,65],"Lumican","Fragility","FRAX","2026-06-24",{"date":68,"type":69},"2026-06-30","ACTUAL",{"date":71,"type":69},"2026-05-15",{"date":73,"type":54},"2026-12-01",{"name":5,"class":6},1]